ACB
Aurora Cannabis, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.96
−0.75%Year over year
Reported trailing growth
- Revenue
- -16.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +7.5%
- EBITDA
- +126.7%
- EPS
- +97.7%
Three-year CAGR
- Revenue
- +12.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026